tbuckley/cabot-search huggingface dataset:
Id2 Promotes Tumor Cell Migration and Invasion through Transcriptional Repression of Semaphorin 3F
Authors: Silvia Coma, Dhara N. Amin, Akio Shimizu, Anna Lasorella, Antonio Iavarone, Michael Klagsbrun
Journal: Cancer Research (2010)

Abstract Id proteins (Id1 to Id4) are helix-loop-helix transcription factors that promote metastasis. It was found that Semaphorin 3F (SEMA3F), a potent inhibitor of metastasis, was repressed by Id2. High metastatic human tumor cell lines had relatively high amounts of Id2 and low SEMA3F levels compared with their low metastatic counterparts. No correlation between metastatic potential and expression of the other Id family members was observed. Furthermore, ectopic expression of Id2 in low metastatic tumor cells downregulated SEMA3F and, as a consequence, enhanced their ability to migrate and invade, two requisite steps of metastasis in vivo. Id2 overexpression was driven by the c-myc oncoprotein. SEMA3F was a direct target gene of the E47/Id2 pathway. Two E-box sites, which bind E protein transcription factors including E47, were identified in the promoter region of the SEMA3F gene. E47 directly activated SEMA3F promoter activity and expression and promoted SEMA3F biological activities, including filamentous actin depolymerization, inactivation of RhoA, and inhibition of cell migration. Silencing of SEMA3F inhibited the E47-induced SEMA3F expression and biological activities, confirming that these E47-induced effects were SEMA3F dependent. E47 did not induce expression of the other members of the SEMA3 family. Id2, a dominant-negative inhibitor of E proteins, abrogated the E47-induced SEMA3F expression and biological activities. Thus, high metastatic tumor cells overexpress c-myc, leading to upregulation of Id2 expression; the aberrantly elevated amount of Id2 represses SEMA3F expression and, as a consequence, enhances the ability of tumor cells to migrate and invade. Cancer Res; 70(9); 3823–32. ©2010 AACR.
Renal vein thrombosis. Complication of primary renal disease and the nephrotic syndrome
Authors: R. A. Older
Journal: JAMA (1978)

THE ASSOCIATION between renal vein thrombosis and the nephrotic syndrome is well documented in the literature. Although some investigators have suggested that renal vein thrombosis precedes the onset of the nephrotic syndrome and hence serves as the initiating event,<sup>1</sup>more recent observations imply that the nephrotic syndrome usually precedes the development of renal vein thrombosis. We report such a progression of events in a patient who had the nephrotic syndrome and in whom idiopathic membranous glomerulonephritis was found on histologic examination of the kidney. Later, renal vein thrombosis complicated the course of the patient's illness. <h3>Report of a Case</h3> A 54-year-old man was hospitalized with peripheral edema, mild hypertension, and proteinuria of three months' duration. The blood pressure on admission was 150/80 mm Hg, and there was pitting edema (2+) to the level of the knees bilaterally. Results of the remaining aspects of the physical examination were unremarkable. Evaluation
1059-7 Impact of late loss on clinical, angiographic and intravascular ultrasound outcomes in the TAXUS IV trial
Authors: Stephen Ellis, Jeffrey J Popma, Neil Weissman, Mark Turco, Ronald Caputo, Patrick Bergin, Joel Greenberg, Albert Raizner, Joerg Koglin, Mary E Russell, Gregg W Stone
Journal: Journal of the American College of Cardiology (2004)
heart doctor father
Authors: Richard Donze
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ELEVATED COPEPTIN IS ASSOCIATED WITH INCREASED 90 DAY MORTALITY IN PATIENTS WITH ACUTE DYSPNEA FROM NON-CARDIAC CAUSES: SECONDARY RESULTS FROM THE BIOMARKERS IN ACUTE HEART FAILURE (BACH) STUDY
Authors: Yang Xue, Justin Tong, Paul Clopton, Judd Landsberg, Patricia Finn, Alan Maisel
Journal: Journal of the American College of Cardiology (2012)
Anti-HIV Substances for Rape Victims
Authors: Ilene M. Foster, John Bartlett
Journal: JAMA (1989)

To the Editor.—  In the age of human immunodeficiency virus (HIV) infection, physicians responsible for the initial treatment of victims of sexual assault would do well to reevaluate and update treatment procedures for female victims of rape.  Historically, victims of sexual assault have been specifically instructed not to wash or douche prior to examination by a physician. Such examinations routinely include a history, examination for injuries, collection of evidence, and counseling. With concern for the possible transmission of HIV, those caring for rape victims should consider topical treatment with nonoxynol 9, 1:10 vinegar solution, or similar anti-HIV substances (B. Voeller, personal communication, September 1988). 1,2   Much as been written in recent years of the efficacy of nonoxynol 9 in inactivation of sexually transmitted disease pathogens including HIV. 1-3 We submit that a treatment revision for victims of sexual assault should include the early administration of nonoxynol 9 as a potential
Vesalius—On the Intestinal Muscles
Authors: Irving A. Beck
Journal: JAMA (1965)

<h3>To the Editor:—</h3> The vivid tribute to the sphincter ani muscle by Bornemeier quoted inThe Journal(<b>193</b>:152 [July 12] 1965) is reminiscent of a classic panegyric: "Nature can never be sufficiently praised for having lavished upon the end of the intestinal rectum, muscles which speedily retract for the purpose of excreting faeces which have pushed into the rectum; and in addition she has provided another muscle which prevents the untimely or involuntary expulsion of excrement." This description (the flavor of which may have suffered in my translation) is that of Vesalius in "De Humani Corporis Fabrica" (1543) a treatise which is monumental because of the original dissections by Vesalius, their superb, dynamic depiction by Jan van Calcar, and the felicitous prose text upon even such a "homely topic." The editorial's suggestion of placing more emphasis upon the study of the humanities in the premedical education could contribute to
Angiotensin-Receptor Blockers for Prevention of Atrial Fibrillation — A Matter of Timing or Target?
Authors: Anne M. Gillis
Journal: New England Journal of Medicine (2009)

Atrial fibrillation is the most common sustained arrhythmia and is associated with substantial morbidity and mortality.1 Antiarrhythmic drug therapy is often ineffective and may cause serious adverse effects, including ventricular proarrhythmia. In the past decade, we have learned much about the electrical, mechanical, and structural remodeling that occurs as a result of atrial fibrillation and that leads to more atrial fibrillation.14 These adaptations include ionic and genomic alterations over the short term and cellular changes over the medium term; fortunately, these effects may be reversible.24 Apoptosis and interstitial fibrosis develop over the longer term and are usually irreversible. . . .
More than working memory rides on long-term memory
Authors: Joaquín M. Fuster
Journal: Behavioral and Brain Sciences (2003)

Single-unit data from the cortex of monkeys performing working-memory tasks support the main point of the target article. Those data, however, also indicate that the activation of long-term memory is essential to the processing of all cognitive functions. The activation of cortical long-term memory networks is a key neural mechanism in attention (working memory is a form thereof), perception, memory acquisition and retrieval, intelligence, and language.
A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel
Authors: Adnan Kastrati, Julinda Mehilli, Helmut Schühlen, Josef Dirschinger, Franz Dotzer, Jurriën M. ten Berg, Franz-Josef Neumann, Hildegard Bollwein, Christian Volmer, Meinrad Gawaz, Peter B. Berger, Albert Schömig
Journal: New England Journal of Medicine (2004)

Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown.We enrolled 2159 patients with coronary artery disease who underwent a percutaneous coronary intervention: 1079 patients were randomly assigned in a double-blind manner to receive abciximab and 1080 patients to receive placebo. All patients were pretreated with a 600-mg dose of clopidogrel at least two hours before the procedure. The primary end point of the trial was the composite of death, myocardial infarction, and urgent target-vessel revascularization within 30 days after randomization.The incidence of the primary end point was 4 percent (45 patients) in the abciximab group, as compared with 4 percent (43 patients) in the placebo group (relative risk, 1.05; 95 percent confidence interval, 0.69 to 1.59; P=0.82). Most adverse events were myocardial infarctions: the incidence was 4 percent (40 patients) in the abciximab group and 4 percent (41 patients) in the placebo group (P=0.91). Twelve patients (1 percent) in the abciximab group and eight patients (1 percent) in the placebo group had major bleeding complications (P=0.37). Profound thrombocytopenia occurred in 10 patients (1 percent) in the abciximab group but in none in the placebo group (P=0.002).Our data suggest that in patients at low-to-intermediate risk who undergo elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel, abciximab is associated with no clinically measurable benefit within the first 30 days.
Chronic Relapsing Febrile Nodular Nonsuppurative Panniculitis (Weber–Christian Disease)
Authors: James C. Brudno
Journal: New England Journal of Medicine (1950)

CHRONIC relapsing febrile nodular nonsuppurative panniculitis is a disease of unknown etiology characterized by recurrent fever associated with a nodular nonsuppurative inflammatory process with necrosis of the subcutaneous and sometimes internal fatty tissue. The nodules occur singly or in clusters varying in diameter from 1 to 12 cm. The process can occur in all parts of the body but particularly on the thighs. The fever persists as long as there are nodules present. These nodules may be painless, particularly if small, or tender, especially when large. The overlying skin is red and raised but is not attached to the subcutaneous . . .
Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B
Authors: Richard S. Garfein, William A. Bower, Cherry M. Loney, Yvan J. F. Hutin, Guo-Liang Xia, Jaspaul Jawanda, Amy V. Groom, Omana V. Nainan, James S. Murphy, Beth P. Bell
Journal: Hepatology (2004)

Death related to acute hepatitis B occurs in approximately 1% of patients. We investigated an outbreak of hepatitis B virus (HBV) infections among injection drug users (IDUs) resulting in several deaths. We conducted a case-control study of fulminant (case patients) and nonfulminant (control patients) HBV infections. We directly sequenced the entire HBV genome from fulminant and nonfulminant cases. From October 1998 to July 2000, 21 acute HBV infections, including 10 fulminant hepatitis B cases, were identified. The median age was 30 (range, 18-49) years, 12 (57%) were female, 20 (95%) were American Indians, and 20 (95%) reported injecting illicit drugs. All patients with fulminant hepatitis B died (case-fatality rate = 47.6%). Case patients (n = 5) and control patients (n = 9) were similar with respect to age, sex, race, and hepatitis C virus serostatus. All case patients used acetaminophen during their illness compared with 44% of control patients (P = .08). Compared with control patients, case patients lost more weight in the 6 months before illness (P = .04); during their illness, they used more alcohol (P = .03) and methamphetamine (P = .04). All 9 isolates sequenced were genotype D, shared 99.7% homology, and included mutations previously described in association with fulminant hepatitis B. In conclusion, a high prevalence of exposure to factors potentiating hepatic damage with acute hepatitis B contributed to the outbreak's high mortality rate; mutations present in the outbreak strain might also have been a factor. Improved vaccination coverage among IDUs has the potential to prevent similar outbreaks in the future.
Screening: reasons to be cautious.
Authors: W W Holland
Journal: BMJ (1993)

temporary stellate block to show the patient the likely outcome in the limb and the effect of Homer's syndrome (which should be a minimal risk).Dorsal sympathectomy may be performed by various "open" operations.The com- plications of open operations include Homer's syndrome, incomplete denervation of T3 and T4 segments, contusion of the brachial plexus, vascular injury, recurrent laryngeal nerve paralysis, and cosmetic problems.These complications outweigh the potential benefits, and many doctors consider open operation to be out of date.The recent development of minimally invasive techniques, which have included percutaneous phenol injection6 and percutaneous radiofrequency ablation7 guided by computed tomography, have provided safer alternatives, but long term effects are unknown.Currently, the most commonly used minimally invasive technique is endoscopic transthoracic sympathectomy,8 which, for the first time, offers a simple and effective treatment for those disabled by severe localised upper limb hyperhidrosis.9-2"The original technique was described well before laparoscopic cholecystectomy but has gained in popularity after the advances in all types of laparoscopic surgery.The first international conference devoted entirely to this operation takes place later this year.The cosmetic result is very good.There is little post- operative pain, and patients need to stay in hospital for less than 48 hours.Bilateral sympathectomies can be carried out at the same operation.Long term complications are similar to those of conventional dorsal sympathectomy, and patients should be warned of these risks.The commonest is compensatory sweating, which may occur in 37-75% ofpatients.10We do not know how to treat this unfortunate consequence, and selecting only severely disabled patients for surgery is essential.If the upper limbs are only mildly affected severe postoperative hyperhidrosis of the trunk, though uncommon, may be even worse.Gustatory sweating is also possible but is only a minor
Oral fingolimod was more effective than placebo for relapsing–remitting multiple sclerosis
Authors: James Hughes
Journal: Annals of Internal Medicine (2010)

ACP Journal Club18 May 2010Oral fingolimod was more effective than placebo for relapsing–remitting multiple sclerosisJames Hughes, MDJames Hughes, MDTamworth Rural Referral Hospital, Tamworth, New South Wales, Australia (J.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-10-201005180-02007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationKappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401. https://pubmed.ncbi.nlm.nih.gov/20089952Clinical Impact RatingsGIM/FP/GP: Neurology: References1 Biogen Idec Australia. Tysabri (natalizumab) safety update, 17 Mar 2010. Google Scholar2 Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk–benefit analysis of natalizumab. Neurology. 2008;71:357-64. [PMID: 18663181] Google Scholar3 Hughes B. First oral therapies for multiple sclerosis anticipated. Nat Rev Drug Discov. 2009;8:831-3. [PMID: 19876030]. Google Scholar4 EMD Serono. Novantrone: mitoxantrone for injection concentrate, additional safety information, Apr 2005. www.novantrone.com/assets/pdf/healthcare_professional_letter.pdf (accessed 23 Mar 2010). Google Scholar5 Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing–remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70:773-80. [PMID: 11385012] Google Scholar Author, Article, and Disclosure InformationAffiliations: Tamworth Rural Referral Hospital, Tamworth, New South Wales, Australia (J.H.)This article was published at Annals.org on 4 May 2010. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOral cladribine was more effective than placebo for relapsing–remitting multiple sclerosis James Hughes Oral fingolimod was more effective than intramuscular interferon for relapsing–remitting multiple sclerosis James Hughes Metrics 18 May 2010Volume 152, Issue 10Page: JC5-7KeywordsDisabilitiesDrugsInterferonsLymphocytesMonoclonal antibodiesMultiple sclerosisQuantitative analysisSafetySerious adverse eventsStandard deviation ePublished: 18 May 2010 Issue Published: 18 May 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Cromolyn vs Placebo
Authors: William C. Deamer
Journal: JAMA (1975)

<h3>To the Editor.—</h3> The letter of Dr. Kit Johnson (230:539, 1974) suggesting that the good results reported (229:787, 1974) in treating chronic asthma with cromolyn sodium may have been due to an irritant effect of sodium sulfate in the placebo—thus producing false-positive results— caused us to reexamine our data. Fortunately, we had recorded baseline symptom and drug usage levels on our patients, which enabled us to document the severity of their asthma prior to entering the study. The mean daily score of patients prior to the trial could thus be compared with their mean daily score while taking placebo as well as with their mean score while taking cromolyn. Symptoms and medication usage while on placebo regimens was less than during base-line observation and dropped even more during cromolyn administration. One could ask why the patient's conditions improved on placebo regimens. I am not sure we have an answer to
Cimetidine and surgery.
Authors: J D Thomson, J B Gallaway
Journal: BMJ (1977)

<b>Objective:</b> To determine efficiency of treatment of XDR-TB with the use of therapy containing linezolid. <b>Content and methods:</b> in St-Petersburg Research Institute of Phthisiopulmonology from 2013 to 2015, 49 patients with XDR lung TB, from 18 to 60 have been treated. Linezolid was used in 24 patients with XDR-TB during the first 6 months of intensive phase of treatment in the dose - 600 mg per day intravenously, by drop infusion in combination with 5-6 anti TB drugs taking into account range of MBT drug resistance – Studied group (group I). Control group -group II(n=25), used 5-6 anti TB drugs without linezolid.We carried out statistical analysis with the use of the program Statistica 6.0. We applied the criterion chi-square(χ2). <b>R</b> <b>esults:</b> in 6 months of therapy symptoms of intoxication were not detected among all patients both in studied and control groups. Negative results of bacterial excretion were registered in I group significantly higher than in II group: 62.5%(14) against 36.0%(9),(p&gt;0.05). Adverse drug reactions were noted with equal frequency in both groups(29.1%(7) vs 32.0%(8). In patients who used linezolid hepatotoxic reactions occurred in 4 of 7 patients, in 3 patients – leukopenia, neutropenia, anemia. In control group - hepatotoxic reactions(5 of 8), diarrhea(3 of 8). When symptomatic therapy was applied adverse drug reactions were resolved. Intensive phase of treatment in both groups lasted 8 months. <b>Conclusion:</b> inclusion of linezolid in combined anti TB therapy resulted in cessation of bacterial excretion in 6 months in twice more frequent cases vs therapy without linezolid. Incidence of adverse drug reactions when linezolid usage was not higher than occurred for standard therapy.
Gender and liver: Is the liver stiffness weaker in weaker sex?
Authors: C. Corpechot, El A. Naggar, R. Poupon
Journal: Hepatology (2006)

We had read with great interest the editorial by D.M. Bissel on the relationships between gender, fibrogenesis and remodeling of liver tissue.1 Several lines of evidence support the notion that sex may have some influence on the progression of fibrosis in chronic liver diseases. Female gender appears to be a protective factor and consistent data from observational and experimental studies suggest a fibrosuppressive effect of estrogens.2-4 However, whether density of extracellular matrix (ECM) in the liver of healthy subjects differs between men and women is unknown. Transient elastography is a new technique that allows noninvasive and reproducible measures of liver stiffness.5 This technique has been proved to be a reliable method for assessing hepatic fibrosis in different chronic liver diseases6-9 However and surprisingly, no systematic data on the stiffness of normal liver have been reported. Herein, we report our experience of liver stiffness measurement in healthy subjects with special regard with gender. We performed a transient elastography of the liver in 71 healthy persons, 33 men and 38 women, who had no history of liver disease, took no drug or alcohol and had normal blood liver tests. The median age was 34 yrs (range, 18-79 years). The median body mass index (BMI) was 22.5 kg.m−2 (range, 17.8-30.8 kg.m−2). Transient elastography was performed using the Fibroscan device (EchoSens, Paris, France) as previously described.9 The median value of liver stiffness was 4.8 kPa (range, 2.5-6.9 kPa). Liver stiffness was not correlated with age, body weight, height and BMI, but was significantly higher in men than in women (5.2 ± 0.7 vs. 4.5 ± 1.0, P < .01 for the Mann-Whitney test, Fig. 1), while BMI (23.4 ± 2.4 vs. 22.6 ± 3.2, NS) and age (35.8 ± 16.1 vs. 39.1 ± 16.4, NS) were similar in the two sexes. Liver stiffness was therefore associated with gender in an independent manner, an observation suggesting an intrinsic difference between men and women in density of the liver ECM. We consider that these data could be an additional argument in favor of a protective effect of female sex and ovarian hormones against the accumulation of ECM and fibrosis in the liver. This observation also suggests that gender potentially should be taken into account in the interpretation of liver stiffness measurement. Distribution of liver stiffness values according to gender in 71 healthy subjects. Means diamonds illustrate groups means and 95% confidence intervals. The gray horizontal bar represents the total sample mean. C. Corpechot*, A. El Naggar*, R. Poupon*, * Service d'Hépatologie, Centre national de référence des maladies inflammatoires du foie et des voies biliaires, Hôpital Saint-Antoine, Paris, France.